Ole Vielemeyer, MD

Publications

2 studies

PI
SPIND 182695 Clofazimine
Novartis Pharmaceuticals Corporation · OPEN TO ACCRUAL (as of 2026)
PI
SPIND Clofazimine 182269
Novartis Pharmaceuticals Corporation · OPEN TO ACCRUAL (as of 2026)

Completed & closed trials (9)

PI
Individual Patient Expanded Access Investigational New Drug Application (IND), Clofazimine. sIND# 157885
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2026)
PI
SPIND Clofazimine 173358
Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2026)
PI
Novartis Multiple Patient Program for Lamprene® (Clofazimine) for the Treatment of Non-Tuberculous Mycobacterial (NTM) Infections
Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2026)
Non-Tuberculous Mycobacterial (NTM) Infections
NCT04334070
PI
SPIND 171032 Clofazimine
Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2025)
PI
SPIND 171521 Clofazimine
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
PI
SPIND 171513
Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
PI
Single Patient IND using Clofazimine to treat Mycobacterium Avium Complex (MAC) Lung Disease with Bronchiectasis but No Cavitation
Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2024)
PI
Single Patient IND using Clofazimine to Treat Mycobacterium Avium Complex (MAC) Lung Disease
Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2024)
PI
Single Patient IND using Clofazimine to treat moderate to severe bronchiectasis and Mycobacterium Avium Complex (MAC)
Novartis Pharmaceuticals Corporation · IRB STUDY CLOSURE (as of 2024)